Argenica Therapeutics Ltd (AU:AGN) has released an update.
Argenica Therapeutics Ltd has initiated Phase 2 clinical trials for its stroke treatment ARG-007, with the first patients already dosed in Australian hospitals. The company also achieved a milestone with the U.S. FDA granting ARG-007 Rare Pediatric Disease Designation for Hypoxic Ischaemic Encephalopathy. Financially, Argenica has bolstered its cash reserves to $6.6 million and raised an additional $12 million, ensuring full funding for ongoing trials in various neurological conditions.
For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.
